Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 June 2023Next earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 21 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
INTS Latest News
Webcast to be Held at 8:00 am ET on Monday, August 14, 2023 WESTPORT, Conn. , Aug. 7, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Intensity) (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it report its financial results for the second quarter ended June 30, 2023, including a corporate update, on Monday, August 14, 2023, before the opening of the U.S. financial markets.
What type of business is Intensity Therapeutics Common stock?
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
What sector is Intensity Therapeutics Common stock in?
Intensity Therapeutics Common stock is in the Healthcare sector
What industry is Intensity Therapeutics Common stock in?
Intensity Therapeutics Common stock is in the Biotechnology industry
What country is Intensity Therapeutics Common stock from?
Intensity Therapeutics Common stock is headquartered in United States
When did Intensity Therapeutics Common stock go public?
Intensity Therapeutics Common stock initial public offering (IPO) was on 30 June 2023
What is Intensity Therapeutics Common stock website?
https://www.intensitytherapeutics.com
Is Intensity Therapeutics Common stock in the S&P 500?
No, Intensity Therapeutics Common stock is not included in the S&P 500 index
Is Intensity Therapeutics Common stock in the NASDAQ 100?
No, Intensity Therapeutics Common stock is not included in the NASDAQ 100 index
Is Intensity Therapeutics Common stock in the Dow Jones?
No, Intensity Therapeutics Common stock is not included in the Dow Jones index
When does Intensity Therapeutics Common stock report earnings?
The next expected earnings date for Intensity Therapeutics Common stock is 14 August 2024